About Trevi Therapeutics, Inc. - Common Stock (TRVI)
Trevi Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for chronic conditions with high unmet medical needs. The company's primary focus is on utilizing its proprietary formulation technology to create treatments for neurological and chronic pain disorders, including pruritus associated with specific dermatological conditions. Through advanced research and clinical trials, Trevi aims to bring new, effective solutions to patients suffering from debilitating symptoms, thereby improving their quality of life. Read More
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
